Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Senseonics Holdings, Inc.SENS · Entity 5469 | GC & Corp. Development Advisor | June 15, 2026 | June 17, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP & Chief Legal Officer | November 17, 2014 | November 19, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Senseonics Holdings, Inc.
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 285,512 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Tax withholding · Disposed 9,545 · Balance 285,512 F1: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.
VERTEX PHARMACEUTICALS INC / MA
Report date November 17, 2014 · Filed November 19, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 72,053 |
Reported balance
After 2014-11-17 transaction · row 1
1 source rowRow 1 · 2014-11-17 · Gift · Disposed 410 · Balance 72,053 F1: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1. F2: Represents two gifts made to a charity and a charity donor-advised fund. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 366 |
Reported balance
Holding disclosure · report date 2014-11-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 366 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1.
F2: Represents two gifts made to a charity and a charity donor-advised fund.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2012 Filed Jun 13, 2012 19:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 9,667 | $0.01 | $96.67 |
DisclosureSEC source: 0001209191-12-033675 · doc4.xml · nonDerivative · entry 1 Horton Kenneth L · CIK 0001552047 · EVP & Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,667 F1 · shares: Restricted stock grant vesting in four annual installments beginning on 6/11/2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.